Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biametrics Launches b-screen® Microarray Screening Device

Published: Wednesday, March 19, 2014
Last Updated: Wednesday, March 19, 2014
Bookmark and Share
Company develops b-portable® for early cancer and infection detection.

Biametrics GmbH has announced the launch of its b-screen® label-free microarray screening device in European markets.

The device is an analysis tool for microarrays in the standard microscope format allowing the detailed studies of biomolecular interactions.

Current applications include bioanalytics, drug discovery, production and quality control. Based on the same technology, the company develops b-portable®, a point-of-care device for early cancer and infection detection.

b-screen® is able to handle different sample types like body fluids (e.g. serum or whole blood) and other relevant complex matrices such as cell culture medium.

Kinetic data can be obtained for almost any kind of biomolecular interaction such as for protein/protein, peptide/protein and small molecules/protein.

b-screen® provides a label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest.

The device can be used with multiple array layouts (highly scalable), uses glass or plastic type substrates and is compatible with almost any common microarray printer. The high-throughput analysis is characterized by a high time resolution (no scanning) at low noise of the optical readout.

No fluorescence labels are needed, which leads to assay conditions as close as possible to the in-vivo situation combined with minimal sample pre-treatment and minimized reagent consumption.

“With b-screen® users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” says Günther Proll, Managing Director of Biametrics.

Proll continued, “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen® provides key advantages over current options like surface plasmon resonance (SPR)”.

Biametrics will present its b-screen® system at Analytica 2014 in Munich, Germany.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!